Publications by authors named "J R Zalcberg"
Aim: The study aimed to describe the incidence of pregnancy-associated colorectal cancer (PACRC) in New South Wales (NSW), Australia, and to examine the perinatal outcomes of women with PACRC and their babies.
Methods: A population-based cohort study was conducted using linked data from NSW. The study group comprised all women diagnosed with colorectal cancer during pregnancy (gestational CRC) or postpartum (postpartum CRC).
Backgrounds: Streamlined, expedited clinical research is fundamental to rapidly test, translate and implement novel treatments into routine care to improve patient outcomes. The National Mutual Acceptance (NMA) scheme was designed to expedite the ethics approval process, however, growing concerns exist about the fragmented time-consuming governance process needed to actually commence clinical research in Australia. This study reports hurdles and barriers encountered while seeking governance approval for the SCANPatient trial.
View Article and Find Full Text PDFArticle Synopsis
- Regorafenib, an oral multikinase inhibitor, was tested in the INTEGRATE IIa trial to see if it improves overall survival in patients with advanced gastric and esophagogastric junction cancer who did not respond to at least two prior treatments.
- The trial compared regorafenib plus supportive care against a placebo with supportive care, enrolling 251 participants and evaluating various outcomes like overall survival (OS), progression-free survival (PFS), and quality of life (QoL).
- Results showed that regorafenib significantly improved OS and PFS compared to placebo, with a median OS of 4.5 months for those receiving regorafenib versus 4.0 months for those on placebo, while also